Skip to main content

Cancer Survivorship

Cancer survivorship in reconstructive urology and urogynecology is the long-term care of patients whose cancer treatment has left durable genitourinary, pelvic-floor, sexual, bowel, pain or psychosocial consequences.

Survivorship is a separate clinical state. The original cancer, the treatment field, the tissue biology, the patient's sexual and continence goals and the feasibility of future surveillance all shape reconstructive decision-making.

Survivorship by Cancer Type​

Cancer / treatment groupMain treatment exposuresReconstructive and urogynecologic problemsWhere covered
Prostate cancerRadical prostatectomy, external beam radiotherapy, brachytherapy, salvage and focal therapyVesicourethral anastomotic stenosis, radiation-induced bulbomembranous stricture, male SUI, ED, climacturia, penile length loss, rectourethral fistula, devastated outletUrethral stricture, VUAS and bladder-neck obstruction; Devastated bladder outlet and diversion; Rectourethral Fistula; Male SUI
Bladder cancerRadical cystectomy with urinary diversion, trimodality therapyStomal and pouch complications, metabolic and upper-tract surveillance, sexual recovery and body image after cystectomy, radiation cystitis after bladder preservation, secondary malignancy in bowel segmentsDevastated bladder outlet and diversion; Radiation and Hemorrhagic Cystitis; Sexual Health and Rehabilitation
Testicular cancerOrchiectomy, retroperitoneal lymph node dissection (RPLND), platinum chemotherapy, radiotherapyTestosterone deficiency, ejaculatory dysfunction after RPLND, testicular prosthesis and body image, secondary malignancyTesticular cancer
Penile cancerOrgan-sparing surgery, glansectomy, partial or total penectomy, inguinal and pelvic node surgery, radiotherapyGlans resurfacing and neoglans, meatal and urethral stenosis, perineal urethrostomy, genital lymphedema, sexual and voiding rehabilitationPenile cancer
Gynecologic, rectal and anal cancers; pelvic exenterationRadical hysterectomy, pelvic radiotherapy and brachytherapy, rectal and anal cancer surgery, exenterationSUI, OAB, fecal incontinence, prolapse, vaginal stenosis, dyspareunia, fistula, neovaginal and perineal reconstruction, lymphedema, chronic pelvic painUrogynecologic reconstruction; Perineal and vaginal reconstruction after exenteration; Chronic Pelvic Pain
Adults treated for childhood GU cancersNephrectomy, pelvic surgery or radiotherapy, alkylating chemotherapy, childhood urinary reconstruction or diversion (Wilms tumor, genitourinary rhabdomyosarcoma)Renal function and hypertension, bladder capacity and voiding function after bladder-sparing therapy, continence, follow-up of the childhood reconstructionAdults treated for childhood GU cancers

Prostate, bladder and pelvic cancers share most of their late effects, so they are covered by reconstructive domain in the sections that follow. Testicular, penile and childhood GU cancers raise problems specific to their treatment and are summarized here.

Testicular cancer​

  • Testosterone deficiency. A cross-sectional study of 31 men with active cancer and 25 controls found similar mean total testosterone but lower calculated free and bioavailable testosterone in the cancer group.[48] In a retrospective cohort of 1,754 US veterans with testicular cancer and 7,117 matched controls, survivors had a higher hazard of recorded testosterone deficiency (HR 6.71, 95% CI 5.78–7.81).[50] In a separate national survey at mean 11-year follow-up, mean testosterone was similar to controls (16.9 versus 17.1 nmol/L), but age-adjusted odds of hypogonadism were higher (OR 3.8, 95% CI 2.0–7.3).[49] A meta-analysis referenced to orchiectomy alone found higher odds of deficiency after standard chemotherapy (OR 1.8, 95% CI 1.3-2.5), non-conventional treatment (double-dose cisplatin, more than four cycles of platinum-based combination chemotherapy, or chemotherapy plus radiotherapy; OR 3.1, 95% CI 2.0-4.8), and infradiaphragmatic radiotherapy (OR 1.6, 95% CI 1.0-2.4).[53] In a separate 5-year longitudinal cohort, 11% of orchiectomy-only patients and 15% of BEP-treated patients had started testosterone substitution.[53][54] See Testosterone Replacement.
  • Testis-sparing surgery. In a systematic review and individual patient-data meta-analysis of 285 patients with 306 testicles treated with partial orchiectomy, hypogonadism was reported in 10/37 with available gonadal-function data (27%) and 8/20 who received adjuvant testicular radiotherapy (40%). These outcomes inform counseling about organ preservation and adjuvant radiotherapy.[55]
  • Ejaculatory function after RPLND. In a nerve-sparing postchemotherapy RPLND series, 136 of 341 patients received a nerve-sparing bilateral template, and 79% of those with follow-up data reported preserved antegrade ejaculation.[57]
  • Secondary malignancy. In a multicenter cohort of 5,848 one-year survivors followed for a median of 14.1 years, solid-cancer risk was 1.8-fold that of the general population (standardized incidence ratio 1.52 after seminoma, 2.21 after nonseminoma) and rose with cumulative platinum and radiotherapy dose.[56]
  • Body image. Prosthesis placement at or after orchiectomy is covered on the Testicular Prosthesis page.

Penile cancer​

  • Radiotherapy of the primary tumor. Reported complications include dysuria, dermatitis, acute mucositis and meatal stenosis; in the cited 67-patient brachytherapy series, urethral stenosis occurred in 9% and penile soft-tissue necrosis in 12%.[51]
  • Recurrence timing after inguinal node dissection. Median time to recurrence differs by site: about 10 months distant, 12 months inguinal, 10.5 months pelvic and 44.5 months local. More than 95% of distant, inguinal and pelvic recurrences occurred within 48 months; the corresponding window for local recurrences was 127 months.[52][61] Recurrence carries a worse-survival hazard that varies by site (inguinal HR 4.5, pelvic HR 2.6, distant HR 4.0; local HR 1.5, not significant).[52] Local recurrence can therefore appear years after organ-sparing reconstruction, and the reconstructed glans or shaft stays under examination long term.
  • Reconstruction and rehabilitation. Organ-sparing options and their sequelae are covered on Glans Resurfacing, Glansectomy With STSG and Glans Reconstruction. Perineal urethrostomy after total penectomy is covered on Blandy Perineal Urethrostomy, and lymphedema after node dissection on Genital Lymphedema.

Adults treated for childhood GU cancers​

Adults treated in childhood for Wilms tumor or genitourinary rhabdomyosarcoma can present to adult reconstructive urology with sequelae of that treatment. Document the original tumor and treatment exposures (nephrectomy, pelvic surgery or radiotherapy, alkylating chemotherapy and any childhood urinary reconstruction or diversion) before starting a fresh adult workup.

In a 164-patient international late-effects report on bladder/prostate rhabdomyosarcoma (median follow-up about 8 years), urinary incontinence at age 6 or older was reported in 31% of patients managed with biopsy only and 27% of those who underwent partial cystectomy. Among patients with available data, abnormal renal function was reported in 19/48 (40%), chronic hematuria in 13/51 (25%) and hydronephrosis in 8/54 (15%); missing outcome data limit extrapolation to all 164 patients.[60] These outcomes reflect 1979-1998 treatment regimens.[60] Lifelong follow-up of childhood reconstructions and diversions is covered on Transitional Urology.

Burden of Dysfunction After Pelvic Cancer Treatment​

Pelvic cancer treatments (radical prostatectomy, radical cystectomy, pelvic exenteration, radical hysterectomy and radiotherapy) are associated with high rates of late urologic and pelvic-floor morbidity.[1][4][37] In observational data, these complications persist or worsen over years.[1][4][37]

Population / exposureSurvivorship signalReconstructive implication
After prostatectomyIn a 29,196-person cohort linked to Medicare data, prostatectomy was associated with a higher 12-year hazard of urinary or sexual complications (HR 7.23) than the untreated comparison group, which largely comprised men without prostate cancer.[1]Screen for SUI, ED, VUAS / BNC and treatment regret early; continence and sexual rehabilitation may require staged reconstruction. For SUI surgery after primary, adjuvant or salvage radiotherapy, the 2024 AUA/GURS/SUFU guideline recommends offering AUS over male slings or adjustable balloons , with counseling about erosion and revision risk.[66]
After pelvic radiotherapyThe same observational cohort found a 12-year urinary or sexual complication HR of 2.76 after radiotherapy. Very large relative hazards for radiation cystitis/proctitis were measured against an unexposed group.[1]Radiation history changes every operation: tissue is hypovascular, graft beds fail more easily, and permanent diversion may be a legitimate endpoint.
Women after pelvic radiotherapyA meta-analysis of 15 observational studies (1,667 women treated with pelvic radiotherapy without prior pelvic surgery or rehabilitation) estimated UI at 37% (n = 805), urgency incontinence at 47% (n = 305), OAB at 42% (n = 349), anal incontinence at 24% (n = 684), pelvic pain at 30% (n = 490), and sexual dysfunction at 19% (n = 877); certainty was moderate for urgency incontinence and OAB and low for the other outcomes.[2]Survivorship visits should include bladder, bowel, pain, and sexual-health screening.
After gynecologic cancer surgeryIn a cohort undergoing hysterectomy for gynecologic cancer, UI affected 83/126 (66%) before surgery and 65/110 (59%) assessed at 3 months; adjuvant therapy was associated with nearly 5-fold higher odds of moderate-to-very severe UI at 3 months (OR 4.98, 95% CI 1.63–15.18).[3]Pelvic-floor symptoms may predate cancer surgery, then worsen after treatment.
ProtecT 12-year prostate-cancer outcomesUrinary leakage persists after prostatectomy, sexual function declines across all arms, and fecal leakage worsens long-term after radiotherapy.[4]Treatment-choice counseling should include late bowel and sexual sequelae.

For localized prostate cancer, AUA/ASTRO requires treatment-choice counseling to incorporate urinary, sexual and bowel risks alongside cancer risk, life expectancy, comorbidities, pre-existing conditions and patient preferences . Its discussion recommends documenting baseline function with standardized instruments.[64]

For radiation biology and operative-field implications, see Radiation & Tissue Effects.

Reconstructive Urology Domains​

Urethral stricture, VUAS, and bladder-neck obstruction​

The 2014 SIU/ICUD consultation described historical posterior stenosis rates of approximately 5–10% after prostatectomy (range 1.4–29%), 4–9% after brachytherapy, 1–13% after external beam radiotherapy and over 40% after salvage prostatectomy.[5] Management should be staged by anatomy, prior radiation, continence status, patient tolerance for future incontinence treatment, and bladder capacity, compliance and refractory cystitis. In a narrative review’s proposed approach, a poorly functioning radiated reservoir may favor diversion over orthotopic reconstruction.[68]

ScenarioWorking approachCounseling point
First-time nonobliterative vesicourethral anastomotic stenosisThe AUA guideline gives a Conditional Recommendation (Grade C) that surgeons may perform dilation, vesicourethral incision or transurethral resection. Success is about 50-80% in first-time cases and appears lower after pelvic radiation.[6]Selected repeat endoscopic treatment may be reasonable; recurrence, obliteration, radiation and patient goals should guide referral for reconstruction.
Radiation-induced bulbomembranous strictureRetrospective multicenter EPA series reported 46/66 successful repairs at median 3.1 years and 119/137 instrumentation-free urethral voiding at mean 32.3 months.[7][8] A single-surgeon study reported 70% and 86% success in sequential cohorts at median 50 and 22 months.[9]In the 137-man cohort, older age and longer stenosis independently predicted recurrence; discuss new or worsened SUI before repair.[8]
Nonobliterative VUAS or bulbomembranous stenosis after prostatectomy and radiotherapyIn a 45-man retrospective series (21 VUAS, 24 bulbomembranous), dorsal onlay BMG urethroplasty had seven recurrences; median follow-up among men without recurrence was 21 months.[10]No de novo SUI was reported among the ten men classified as continent before repair; 29/45 had baseline incontinence and six had unknown status. Continence was assessed 3–6 months postoperatively.[10]
Complex radiation outlet / devastated bladder outletRobotic reconstruction and diversion are options in selected cases. Free ileal flap reconstruction remains highly preliminary: the cited six-patient series reported four functional reconstructions at median 204-day follow-up.[6][11][14]The decision is often between reconstruction and planned permanent diversion rather than one more endoscopic attempt.

A meta-analysis of eight retrospective series (256 patients) estimated new SUI at 19% (95% CI 10–31%) after urethroplasty for radiation-induced stenosis.[12] The older 40% figure describes persistent incontinence after urethroplasty, not exclusively de novo SUI.[13] A separate 137-patient EPA cohort reported subsequent AUS placement in 30 patients (21.9%).[8] See Radiation-Induced Posterior Urethral Stenosis for the full management pathway, and Urethral Reconstruction, Bladder Neck Reconstruction, and Incontinence.

Functional preservation and new survivorship evidence​

NeuroSAFE PROOF (2025) randomized 407 men; 381 underwent surgery and 344 supplied the 12-month primary outcome. Participants had good unaided erectile function before prostatectomy. NeuroSAFE-guided nerve sparing improved 12-month IIEF-5 scores versus standard robot-assisted surgery (12.7 versus 9.7; adjusted difference 3.18, 95% CI 1.62–4.75). Continence scores favored NeuroSAFE at three months, but the six-month difference was not significant.[38]

Testosterone in prostate cancer survivors (2026). A randomized, placebo-controlled trial enrolled 136 hypogonadal men with organ-confined Gleason 3+3 or 3+4 cancer treated by prostatectomy and undetectable PSA for at least two years; 125 completed 12 weeks. Testosterone improved sexual activity and desire, but not erectile function. No biochemical recurrence was observed during this short study. Coordinate any treatment with the cancer and endocrine and sexual-medicine teams.[39]

IMvigor011 (2025) informs post-cystectomy oncology coordination: among 761 enrolled patients, 250 who became ctDNA-positive were randomized to atezolizumab or placebo. Disease-free survival favored treatment (median 9.9 versus 4.8 months; HR 0.64, 95% CI 0.47–0.87), as did overall survival (median 32.8 versus 21.1 months; HR 0.59, 95% CI 0.39–0.90). Patients remaining ctDNA-negative were observed and not randomized. Confirm current oncologic eligibility and treatment guidance with the treating team.[40]

Devastated bladder outlet and diversion​

When the outlet is densely fibrotic, necrotic, fistulized, intolerably painful, or paired with refractory incontinence, urinary diversion with or without cystectomy may be the most restorative operation.[14] A prospective diversion cohort enrolled 55 patients; 47 provided paired preoperative and postoperative responses, with completion varying across questionnaires and median follow-up of 47.7 months.[15] Reported health, pain and quality of life improved with low decision regret, but there was no untreated comparison group.[15]

A separate retrospective review of 34 women who underwent diversion for late adverse effects of gynecologic radiotherapy reported the perioperative burden distinctly: 76.5% received noncontinent (incontinent) diversion, 79.4% had a complication within 90 days, 26.5% had a high-grade (Clavien ≥3) complication, and 32% were readmitted within 30 days.[58] Rates of high-grade complications did not differ significantly by diversion type, concurrent cystectomy, or CT-defined sarcopenia.[58]

The survivorship version of diversion counseling should include:

  • Whether to retain or remove the bladder; in a 24-patient retrospective benign-disease diversion cohort that included radiation or hemorrhagic cystitis, 8 developed pyocystis and 6 later required cystectomy.[71]
  • Whether the patient can manage a stoma, catheterizable channel, or neobladder.
  • Prior bowel resection, pelvic radiation dose, renal function, B12 risk, metabolic acidosis risk, mucus burden, and future surveillance feasibility.
  • The possibility that pain relief and infection control may be the primary goals, even when continence cannot be restored.

After cystectomy for bladder cancer, NCCN follow-up includes renal-function and electrolyte testing and upper-tract imaging. It specifies annual B12 testing after the first year based on clinical judgment (category 2A).[62] The intervals and differences from AUA follow-up are detailed in Renal Function and Metabolic Surveillance.

See Urinary Diversion, Mucus Management, Vitamin B12 Supplementation, and Urinary Acidifiers & Alkalinizers.

Radiation / hemorrhagic cystitis​

See the dedicated Radiation and Hemorrhagic Cystitis page for grading, the full management ladder and the contracted radiated bladder; the summary below is the survivorship orientation.

Chronic radiation cystitis affects approximately 5-10% of patients after pelvic radiotherapy and can present months to decades after treatment.[18] Management is stepwise:

  1. Stabilize bleeding: catheter drainage, clot evacuation, continuous bladder irrigation, correction of coagulopathy, and cystoscopic fulguration when needed.
  2. Evaluate hematuria and irritative symptoms for other causes, including infection, stones and recurrent or new malignancy; neither radiation history nor bacteriuria establishes the diagnosis by itself.
  3. Consider hyperbaric oxygen therapy for persistent symptomatic radiation cystitis in patients resembling the RICH-ART population. RICH-ART randomized 87 patients and analyzed 79, finding a 10.1-point greater improvement in EPIC urinary total score than standard care at 6–8 months (95% CI 2.2–18.1); it excluded bleeding requiring >500 mL transfusion in the preceding four weeks, a permanent urinary catheter, bladder capacity <100 mL and bladder fistula.[16] The five-year single-group report included 70 HBOT-treated patients after control crossover; 39/70 had a five-year EPIC observation, and 9/70 received additional HBOT for recurrent symptoms. Symptom improvement persisted among observed patients.[16][18]
  4. Consider selected intravesical treatments according to evidence and bleeding severity. Glycosaminoglycan replacement has limited clinical data; in a single-center 51-patient cohort it was instilled after active bleeding had settled.[19] RADA16 application has preliminary evidence from 15 patients.[20]
  5. Reserve salvage cystectomy and diversion for refractory, life-altering bleeding, pain, contracted bladder, fistula, or repeated hospitalization.[22]

A 2024 meta-analysis of 14 studies (556 patients) reported complete hematuria remission in 55% of patients receiving HBOT (95% CI 51–59%), but the evidence was heterogeneous; benefit and treatment risks still require individualized discussion.[17] Oral chlorophyllin is under investigation in a phase II study.[21]

Secondary malignancy after reconstruction​

Secondary malignancies arising within urologic reconstructions are rare but high-consequence. In an 11-case multi-institutional series, tumors appeared at a median of 36 years after reconstruction, were predominantly adenocarcinoma, often presented at advanced stage, and were aggressive.[23] Lifelong symptom and reconstruction follow-up applies when bowel is incorporated into the urinary tract. Investigate concerning symptoms and follow the relevant condition-specific guidance.

Urogynecologic Reconstruction and Pelvic-Floor Survivorship​

NCCN disease-specific survivorship guidance for uterine, cervical, vulvar, and vaginal cancer emphasizes that surgery and radiotherapy may cause adhesions, urinary and bowel complications, pelvic-floor dysfunction, lymphedema, sexual dysfunction, and chronic pain.[24][25][26][27]

Pelvic-floor survivorship should separate three overlapping problems:

ProblemMore linked to surgeryMore linked to radiotherapyReconstructive frame
Stress urinary incontinence / prolapseRadical pelvic surgery, hysterectomy, denervation, fascial disruptionMay coexistConsider pelvic floor PT first; sling, bulking, Burch, AUS, or prolapse repair only after oncologic anatomy and tissue quality are understood.
Urgency, OAB, bladder pain, vaginal stenosisBladder denervation and perioperative injuryRadiation cystitis, fibrosis, stenosis, mucosal fragilityTreat GSM / atrophy, pain, and bladder hypersensitivity before labeling surgery a failure.
Fecal / anal incontinence and dyspareuniaExenteration, rectal surgery, radical hysterectomyRectal dose, proctitis, fibrosisMultidisciplinary pelvic-floor care is usually required.

Combined gynecologic oncology and urogynecology surgery is feasible in selected patients; in a single-center retrospective matched cohort (61 combined operations, 61 oncology-only operations; mostly endometrial cancer in the combined group), 90-day complications were 84% versus 41%, mainly early urinary tract infections, and time from oncology consultation to surgery was 32 versus 17 days.[72] A joint AUGS-SGO clinical consensus statement (Delphi; 35 statements, 28 reaching consensus on first review and 4 more after revision) notes that about half of women with gynecologic cancer have significant pelvic floor symptoms, yet fewer than 6% of cancer operations include an incontinence or prolapse procedure.[42] It advises that concomitant pelvic floor surgery may be offered to any patient with a bothersome pelvic floor disorder who is having gynecologic cancer surgery, provided coordination does not cause undue morbidity; that cancer surgery may be delayed no more than 6 weeks to accommodate it; and that prolapse or SUI surgery is preferably done before radiation when it neither delays treatment nor substantially alters anatomy for radiation planning.[42] In a 102-patient concurrent-surgery series, only 29 patients had malignant or premalignant disease and 73 had benign indications.[28] The 9.8% complication rate included transfusion and reoperation.[28] A systematic review of pelvic-floor dysfunction after gynecologic cancer surgery and adjuvant therapy highlights conservative management - pelvic floor muscle training, biofeedback, vaginal dilators, and lifestyle modification - before surgical escalation.[29]

EMBRACE-I (2025) adds prospective observational evidence: 882 of 1,416 cervical-cancer patients had sufficient follow-up for analysis. Regular dilation, combining dilator use, sexual activity, or both reported at at least half of visits, was associated with less grade ≥2 stenosis at five years (23% versus 37%; adjusted HR 0.63). Mild dryness and bleeding were more frequent.[41]

See Prolapse Repair, Incontinence, Pelvic Floor Physical Therapy, GSM, and Female Sexual Dysfunction.

Perineal and Vaginal Reconstruction After Exenteration​

For selected patients with advanced pelvic malignancy, radical surgical excision may be the only curative option; exenteration with reconstruction can be part of that approach.[30] Neovaginal and perineal reconstruction should be planned around dead-space obliteration, durable pelvic-floor closure, sexual goals, radiation history, stoma / diversion placement, and donor-site morbidity.

A multicenter exenteration study included 334 patients, of whom 77 underwent neovaginal reconstruction. Within those 77, 66% had no recorded long-term morbidity, 7% developed neovaginal stenosis and 5.2% had procedure-specific major morbidity.[30] Flap options include VRAM, gracilis, IGAP, lotus petal, and other regional or free-tissue strategies.[31][32] A separate flap-reconstruction study had 36 respondents among 71 eligible patients; reported quality of life could be high despite impaired sexual function. Response limits reinforce the importance of individual sexual rehabilitation and expectation-setting.[32]

Postoperative protocol. One center's practice after a rotational pelvic or perineal flap has been described: sitting is avoided for at least 5 days while log-roll transfers and short ambulation are allowed, then a staged sitting protocol begins at 5 minutes four times daily, increasing by 5 minutes each day toward 1 hour as tolerated. A Foley catheter is kept for 5 days, and surgical drains stay until output is under 20 mL for 2 consecutive days. After reconstruction of the vaginal cavity, a speculum exam at 4 weeks checks that suture lines are intact and tissue is viable before starting twice-daily dilation, with dilator size advanced after 2 weeks if there is no pain or tightness. This sequence is the cited authors' practice rather than a validated universal protocol.[59]

See Genital Reconstruction and Fistula Repair. For the canonical flap and graft toolkit, see Foundations: Flaps in GU Reconstruction and Foundations: Grafts in GU Reconstruction.

Sexual Health and Rehabilitation​

Sexual dysfunction is a common survivorship problem that is often not addressed. NCCN Survivorship recommends regular screening using validated tools such as FSFI, SHIM, and PROMIS SexFS, with proactive clinician initiation rather than waiting for the patient to volunteer concerns.[33] ASCO similarly recommends that a member of the care team initiate discussion at diagnosis and reassess throughout follow-up.[36]

Patient groupCommon issuesInitial rehabilitation frame
Cisgender male survivorsED after prostatectomy / cystectomy / radiotherapy, climacturia, penile shortening, low testosterone, Peyronie's overlap, orgasmic changePDE5 inhibitors, VED / traction where appropriate, ICI, intraurethral alprostadil where available (MUSE is discontinued in the US), penile prosthesis for refractory ED, testosterone evaluation when clinically appropriate
Cisgender female survivorsDyspareunia, dryness, vaginal stenosis, arousal / orgasm change, body-image distress, pain with penetration, sexual avoidanceLubricants / moisturizers, topical lidocaine, low-dose vaginal estrogen or DHEA when oncologically appropriate, dilators, pelvic floor PT, psychosexual counseling
Diversion / exenteration survivorsAltered body image, stoma-related intimacy barriers, neovaginal stenosis, loss of ejaculation or vaginal depth, relationship distressExplicit counseling on self-pleasure, non-penetrative intimacy, pouch / appliance management, partner communication, referral to sexual-medicine specialists

After radical cystectomy, qualitative data show that many women receive little or no information about sexual dysfunction and want more complete counseling, including self-pleasure and non-intercourse intimacy.[34] Post-cystectomy patients of all sexes may experience significant sexual distress.[35]

A cross-sectional analysis at baseline, 1 month, 6 months, and 1, 2, 4, 6 and 8 years after treatment compared 139 neobladder and 85 ileal conduit patients with 112 cystoscopy patients. The Bladder Cancer Index assessed urinary, bowel and sexual outcomes, and the EORTC Body Image Scale assessed body image. Both diversion groups had worse body-image scores than the cystoscopy reference group, with no difference between diversions; scores improved at later time points, although the neobladder group did not return to baseline.[45] A separate systematic review and meta-analysis of 29 studies (3,754 patients) found no difference in overall quality of life between continent and incontinent diversion on pooled quantitative scores, but a qualitative synthesis found that neobladder patients had superior emotional function and body image compared with cutaneous diversion.[46]

See Male Sexual Dysfunction, Penile Implants, and Female Sexual Dysfunction.

Chronic Pelvic Pain​

Cancer survivors with chronic GI, urinary, or pelvic pain should be evaluated for recurrent cancer and treatable complications, but persistent pain also deserves a rehabilitation pathway. NCCN Survivorship frames pelvic pain care as multidisciplinary: urology, gynecology, physical medicine and rehabilitation, pelvic-floor physical therapy, bowel regimen, hydration, psychosocial care, and selected neuromodulation for chronic cystitis-type pain.[33]

In reconstructive practice, chronic pelvic pain should trigger a structured review:

  • Is there radiation cystitis, contracted bladder, fistula, infection, stone, obstruction, retained bladder syndrome, or pubic symphysis osteomyelitis?
  • Is there pelvic-floor overactivity, levator spasm, neuropathic pain, vaginal stenosis, or dyspareunia?
  • Is the goal restoration of anatomy, pain control, continence, sexual function, or the ability to stop repeated emergency visits?
  • Would another reconstructive attempt help, or would diversion / extirpation better match the patient's goals?

Survivorship Care Model​

The NCCN Survivorship framework defines six standards that apply directly to reconstructive urology and urogynecology survivors: recurrence surveillance and subsequent-cancer screening; monitoring long-term physical, psychosocial, cognitive, and immunologic effects; prevention and detection of late effects; management of cancer-related syndromes with referral; coordination between primary care and specialists; and planning for ongoing care including physical activity, nutrition, alcohol avoidance, smoking cessation, and weight management.[33]

For UTUC survivors, AUA/SUO 2023 advises considering nephrology referral for reduced or deteriorating renal function after nephroureterectomy or another intervention . It also advises discussing disease-related stress and promoting smoking cessation, exercise and a healthy diet .[63]

For localized prostate cancer survivors, AUA/ASTRO recommends post-treatment PSA and symptom assessment ; its discussion recommends routinely querying urinary, bowel and sexual function with validated instruments. Continued symptom management and engagement with professional or community resources are recommended , with pelvic-floor rehabilitation and psychosexual therapy among the referral options described.[64]

For survivors considering salvage RT after radical prostatectomy, AUA/ASTRO/SUO 2024 calls for counseling about urinary, erectile and bowel risks alongside risk from recurrent cancer, life expectancy, comorbidities and patient preferences . Its discussion advises documenting baseline urinary, bowel and sexual function with standardized instruments and identifies late hemorrhagic cystitis and secondary malignancies as potential harms.[65]

In a SEER cohort of patients with bladder cancer, the suicide standardized mortality ratio was 2.71 versus the general population.[43] In a retrospective SEER-Medicare cohort of 3,709 patients aged 66 years or older with clinical T2–T4a bladder cancer and no psychiatric diagnosis in the 12 months before treatment, radical cystectomy (with or without radiotherapy or chemotherapy) was associated with a higher risk of psychiatric diagnosis within one year than radiotherapy and/or chemotherapy without cystectomy (HR 1.19).[44] A post-treatment psychiatric diagnosis was associated with worse one-year overall (HR 2.80) and cancer-specific (HR 2.39) survival than no post-treatment psychiatric diagnosis.[44] NCCN recommends distress screening for all patients with cancer using the Distress Thermometer and Problem List; elevated scores prompt further evaluation and referral, with separate suicide-risk assessment when indicated.[67]

A practical clinic template is:

Visit domainMinimum survivorship screenWhy it matters reconstructively
Cancer status and field historyCancer type, stage, surgery, radiation dose / field, chemotherapy, immunotherapy, recurrence statusDetermines tissue biology, operative risk, and whether symptoms might represent recurrence.
Urinary functionPads, catheterization, retention, UTIs, hematuria, urgency, pain, renal function, upper-tract imagingIdentifies outlet obstruction, radiation cystitis, diversion complications, and reconstruction failure.
Bowel and pelvic-floor functionFI, constipation, radiation proctitis, pelvic-floor spasm, prolapse symptomsUrinary reconstruction often fails if bowel dysfunction and pelvic-floor pain are ignored.
Sexual health and body imageDesire, arousal, erections, lubrication, dyspareunia, orgasm, intimacy goals, distressSexual rehabilitation should be offered before and after reconstruction.
Psychosocial and decision qualityRegret, anxiety, depression, distress (NCCN Distress Thermometer), suicidal ideation assessed separately[67], partner concerns, work / activity limitations, ostomy distressComplex reconstruction is preference-sensitive; regret and distress change the operative endpoint, and bladder-cancer survivors carry an elevated suicide risk that warrants routine screening.
Long-term surveillanceSubsequent primary cancers, reconstructed urinary tract surveillance, stoma / pouch / augmented bladder reviewSecondary cancers and bowel-segment complications may appear decades later.[23]

Smoking cessation as part of survivorship care​

Smoking cessation has been framed as a fourth pillar of cancer treatment alongside surgery, systemic therapy and radiation.[47] A brief validated screening question at every visit (Ask), a clear recommendation to quit (Advise), referral to a tobacco-treatment program or a quitline (Refer), and pharmacotherapy such as varenicline for 12 weeks, with an additional 12 weeks for successful quitters[73], or combination nicotine-replacement therapy (Prescribe), are the standard components. For reconstructive counseling, smoking was associated with stricture recurrence after urethroplasty in pooled observational studies (adjusted RR 1.35, 95% CI 1.002–1.81).[69] A 2,251-man NSQIP analysis, including 573 flap- or graft-augmented repairs, did not detect a smoking association with 30-day wound complications in the augmented subgroup.[70]

Key Takeaways​

  • Pelvic cancer treatment creates durable urologic, pelvic-floor, bowel, sexual, and pain syndromes.[37][4]
  • Prior radiation changes the reconstructive equation: success rates, incontinence risk, graft reliability, fistula risk, and the threshold for urinary diversion all shift.
  • Reconstructive procedures can improve quality of life, but they need survivorship-specific counseling about morbidity, staged care, sexual function, and lifelong surveillance.
  • Sexual health screening should be routine and proactive for all survivors.
  • Care is multidisciplinary: reconstructive urology, urogynecology, oncology, pelvic-floor PT, sexual medicine, psychology, pain medicine, ostomy care, and primary care.

See Also​

References​

1. Unger JM, Till C, Tangen CM, et al. Long-term adverse effects and complications after prostate cancer treatment. JAMA Oncol. 2024;10(12):1654-1662. doi:10.1001/jamaoncol.2024.4397

2. Perez CDA, Rocha AKL, Volpato MP, et al. Prevalence of pelvic floor dysfunction in women after pelvic radiotherapy: systematic review and meta-analysis. Int Urogynecol J. 2026. doi:10.1007/s00192-026-06557-z

3. Brennen R, Lin KY, Denehy L, et al. Natural history of pelvic floor disorders before and after hysterectomy for gynaecological cancer. BJOG. 2024;131(11):1545-1554. doi:10.1111/1471-0528.17870

4. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid. 2023;2(4):EVIDoa2300018. doi:10.1056/EVIDoa2300018

5. Herschorn S, Elliott S, Coburn M, Wessells H, Zinman L. SIU/ICUD consultation on urethral strictures: posterior urethral stenosis after treatment of prostate cancer. Urology. 2014;83(3 Suppl):S59-S70. doi:10.1016/j.urology.2013.08.036

6. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral stricture disease guideline amendment (2023). J Urol. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482

7. Hofer MD, Zhao LC, Morey AF, et al. Outcomes after urethroplasty for radiotherapy induced bulbomembranous urethral stricture disease. J Urol. 2014;191(5):1307-1312. doi:10.1016/j.juro.2013.10.147

8. Voelzke BB, Leddy LS, Myers JB, et al. Multi-institutional outcomes and associations after excision and primary anastomosis for radiotherapy-associated bulbomembranous urethral stenoses following prostate cancer treatment. Urology. 2021;152:117-122. doi:10.1016/j.urology.2020.11.077

9. Fuchs JS, Hofer MD, Sheth KR, et al. Improving outcomes of bulbomembranous urethroplasty for radiation-induced urethral strictures in post-Urolume era. Urology. 2017;99:240-245. doi:10.1016/j.urology.2016.07.031

10. Sterling J, Simhan J, Flynn BJ, et al. Multi-institutional outcomes of dorsal onlay buccal mucosal graft urethroplasty in patients with postprostatectomy, postradiation anastomotic stenosis. J Urol. 2024;211(4):596-604. doi:10.1097/JU.0000000000003848

11. Sorenson TJ, Elbakry AA, Ratanapornsompong W, et al. Posterior urethral reconstruction with ileal chimeric free flap: a novel approach for management of radiation-induced devastated bladder outlet. Urology. 2026;208:159-165. doi:10.1016/j.urology.2025.10.014

12. Sapienza LG, Ning MS, Carvalho EF, et al. Efficacy and incontinence rates after urethroplasty for radiation-induced urethral stenosis: a systematic review and meta-analysis. Urology. 2021;152:109-116. doi:10.1016/j.urology.2021.02.014

13. Meeks JJ, Brandes SB, Morey AF, et al. Urethroplasty for radiotherapy induced bulbomembranous strictures: a multi-institutional experience. J Urol. 2011;185(5):1761-1765. doi:10.1016/j.juro.2010.12.038

14. Martins FE, Holm HV, Lumen N. Devastated bladder outlet in pelvic cancer survivors: issues on surgical reconstruction and quality of life. J Clin Med. 2021;10(21):4920. doi:10.3390/jcm10214920

15. Woodle T, Kurtzman JT, Ramsay J, McCormick B, Myers JB. A prospective analysis of patient-reported health-related quality of life outcomes following urinary diversion for pelvic radiation-related injury. Urology. 2026;214:105-110. doi:10.1016/j.urology.2026.01.017

16. Oscarsson N, Muller B, Rosen A, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol. 2019;20(11):1602-1614. doi:10.1016/S1470-2045(19)30494-2

17. Yang TK, Wang YJ, Li HJ, et al. Efficacy and safety of hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis: a systematic review and meta-analysis. J Clin Med. 2024;13(16):4724. doi:10.3390/jcm13164724

18. Oscarsson N, Rosen A, Muller B, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): long-term follow-up of a randomised controlled, phase 2-3 trial. EClinicalMedicine. 2025;83:103214. doi:10.1016/j.eclinm.2025.103214

19. Sanguedolce F, Meneghetti I, Bevilacqua G, et al. Intravesical instillation with glycosaminoglycan replacement treatment in patients suffering radiation-induced haemorrhagic cystitis: when and which patients can benefit most from it? Urol Oncol. 2022;40(7):344.e19-344.e25. doi:10.1016/j.urolonc.2022.02.013

20. Kam J, Abu-Ghanem Y, Del Guidice F, et al. Cystoscopic application of RADA16 peptide for refractory haematuria from radiation cystitis. BJU Int. 2025. doi:10.1111/bju.70075

21. Prakash G, Sharma D, Chopra S, et al. A phase II study of oral chlorophyllin in haemorrhagic cystitis secondary to radiation therapy for pelvic malignancies (CLARITY). J Clin Oncol. 2024;42(Suppl 23):48. doi:10.1200/JCO.2024.42.23_suppl.48

22. Pascoe C, Duncan C, Lamb BW, et al. Current management of radiation cystitis: a review and practical guide to clinical management. BJU Int. 2019;123(4):585-594. doi:10.1111/bju.14516

23. Cornell C, Khani F, Osunkoya AO, et al. Secondary malignancy after urologic reconstruction procedures: a multi-institutional case series. Hum Pathol. 2022;119:69-78. doi:10.1016/j.humpath.2021.11.004

24. National Comprehensive Cancer Network. Uterine Neoplasms. Updated 2025-11-14. https://www.nccn.org

25. National Comprehensive Cancer Network. Cervical Cancer. Updated 2025-11-10. https://www.nccn.org

26. National Comprehensive Cancer Network. Vulvar Cancer. Updated 2026-01-06. https://www.nccn.org

27. National Comprehensive Cancer Network. Vaginal Cancer. Updated 2025-12-04. https://www.nccn.org

28. Kohut A, Whitaker T, Walter L, et al. Feasibility of combining pelvic reconstruction with gynecologic oncology-related surgery. Int Urogynecol J. 2023;34(1):177-183. doi:10.1007/s00192-022-05212-7

29. Kurtulus D, Arkan K, Suceken FY, et al. Pelvic floor dysfunction following gynecologic cancer surgery and adjuvant therapy: epidemiology, mechanisms, and management - a systematic review. Int Urogynecol J. 2026;37(8):2353-2363. doi:10.1007/s00192-026-06522-w

30. PelvEx Collaborative. A review of functional and surgical outcomes of gynaecological reconstruction in the context of pelvic exenteration. Surg Oncol. 2024;52:101996. doi:10.1016/j.suronc.2023.101996

31. Bini A, Stavrianos S. Pelvic and perineal reconstruction after bowel, gynecological or sacral tumor resection: a case series. J Clin Med. 2025;14(9):3172. doi:10.3390/jcm14093172

32. Assi H, Persson A, Palmquist I, et al. Sexual and functional long-term outcomes following advanced pelvic cancer and reconstruction using vertical rectus abdominis myocutaneous and gluteal myocutaneous flap. Eur J Surg Oncol. 2021;47(4):858-865. doi:10.1016/j.ejso.2020.09.025

33. National Comprehensive Cancer Network. Survivorship. Updated 2026-04-08. https://www.nccn.org

34. Ceasar RC, Ladi-Seyedian SS, Escobar D, et al. "I think my vagina is still there?": women's perspectives on sexual function and dysfunction following radical cystectomy for bladder cancer, a qualitative study. J Sex Med. 2024;21(5):464-470. doi:10.1093/jsxmed/qdae025

35. Zhang M, Zhou Y. Sexual distress in patients after radical cystectomy for bladder cancer: a qualitative study. Support Care Cancer. 2026;34(2):151. doi:10.1007/s00520-026-10380-z

36. Carter J, Lacchetti C, Andersen BL, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario guideline. J Clin Oncol. 2018;36(5):492-511. doi:10.1200/JCO.2017.75.8995

37. Adams E, Boulton MG, Horne A, et al. The effects of pelvic radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life. Clin Oncol (R Coll Radiol). 2014;26(1):10-17. doi:10.1016/j.clon.2013.08.003

38. Dinneen E, Almeida-Magana R, Al-Hammouri T, et al. Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial. Lancet Oncol. 2025;26(4):447-458. doi:10.1016/S1470-2045(25)00091-9

39. Bhasin S, Burnett AL, Gagliano-Jucá T, et al. Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial. JAMA Intern Med. 2026;186(7):805-814. doi:10.1001/jamainternmed.2026.1343

40. Powles T, Kann AG, Castellano D, et al. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N Engl J Med. 2025;393(24):2395-2408. doi:10.1056/NEJMoa2511885

41. Kirchheiner K, Zaharie A, Smet S, et al. Association Between the Regular Use of Vaginal Dilators and/or Sexual Activity and Vaginal Morbidity in Locally Advanced Cervical Cancer Survivors: An EMBRACE-I Study Report. Int J Radiat Oncol Biol Phys. 2025;121(2):452–464. doi:10.1016/j.ijrobp.2024.09.011

42. Wohlrab K, Robison K, Rahn DD, et al. Safety and feasibility of concomitant urogynecologic and gynecologic oncology surgical procedures. Urogynecology (Phila). 2026;32(2):76-89. doi:10.1097/SPV.0000000000001804. AUGS-SGO joint Clinical Consensus Statement.

43. Klaassen Z, DiBianco JM, Jen RP, et al. The Impact of Radical Cystectomy and Urinary Diversion on Suicidal Death in Patients With Bladder Cancer. J Wound Ostomy Continence Nurs. 2016;43(2):152-157. doi:10.1097/WON.0000000000000188

44. Jazzar U, Yong S, Klaassen Z, et al. Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer. 2018;124(15):3127-3135. doi:10.1002/cncr.31404

45. Hedgepeth RC, Gilbert SM, He C, Lee CT, Wood DP Jr. Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions. Urology. 2010;76(3):671-675. doi:10.1016/j.urology.2010.01.087

46. Yang LS, Shan BL, Shan LL, et al. A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg Oncol. 2016;25(3):281-297. doi:10.1016/j.suronc.2016.05.027

47. Fiore MC, D'Angelo H, Baker T. Effective Cessation Treatment for Patients With Cancer Who Smoke-The Fourth Pillar of Cancer Care. JAMA Netw Open. 2019;2(9):e1912264. doi:10.1001/jamanetworkopen.2019.12264

48. Garcia JM, Li H, Mann D, et al. Hypogonadism in male patients with cancer. Cancer. 2006;106(12):2583-2591. doi:10.1002/cncr.21889

49. Nord C, Bjøro T, Ellingsen D, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol. 2003;44(3):322-328. doi:10.1016/s0302-2838(03)00263-x

50. Pandit K, Riviere P, Morgan K, et al. Incidence of Erectile Dysfunction and Testosterone Deficiency in Testicular Cancer Survivors. J Urol. 2025;213(1):71-79. doi:10.1097/JU.0000000000004259

51. Crook J, Ma C, Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World J Urol. 2009;27(2):189-196. doi:10.1007/s00345-008-0309-5

52. Chakiryan NH, Dahmen A, Bandini M, et al. Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. J Urol. 2021;206(4):960-969. doi:10.1097/JU.0000000000001790

53. Bandak M, Jørgensen N, Juul A, et al. Testosterone deficiency in testicular cancer survivors - a systematic review and meta-analysis. Andrology. 2016;4(3):382-388. doi:10.1111/andr.12177

54. Bandak M, Jørgensen N, Juul A, et al. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin. Eur Urol Focus. 2018;4(4):591-598. doi:10.1016/j.euf.2016.11.018

55. Grogg JB, Dursun ZH, Beyer J, et al. Oncological and functional outcomes after testis-sparing surgery in patients with germ cell tumors: a systematic review of 285 cases. World J Urol. 2022;40(9):2293-2303. doi:10.1007/s00345-022-04048-6

56. Groot HJ, Lubberts S, de Wit R, et al. Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. J Clin Oncol. 2018;36(24):2504-2513. doi:10.1200/JCO.2017.77.4174

57. Pettus JA, Carver BS, Masterson T, et al. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology. 2009;73(2):328-331. doi:10.1016/j.urology.2008.08.501

58. Smith D, Albersheim J, Moses R, et al. Outcomes of Urinary Diversion for Late Adverse Effects of Gynecologic Radiotherapy. Urology. 2020;144:214-219. doi:10.1016/j.urology.2020.06.040

59. Singh J, Roubaud MS, Smith TG III, Westney OL. Options for Surgical Reconstruction of the Heavily Irradiated Pelvis. In: Martins FE, Holm HV, Sandhu JS, McCammon KA, eds. Female Genitourinary and Pelvic Floor Reconstruction. Springer; 2023:1063–1098.

60. Raney B, Anderson J, Jenney M, et al. Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: a report from the international workshop. J Urol. 2006;176(5):2190-2194; discussion 2194-2195. doi:10.1016/j.juro.2006.07.064

61. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Penile Cancer. Version 2.2026. June 5, 2026.

62. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 3.2026. August 6, 2026. BL-E 3–4 of 6. Guideline.

63. Coleman JA, Clark PE, Bixler BR, et al. Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline. J Urol. 2023;209(6):1071-1081. doi:10.1097/JU.0000000000003480

64. Eastham JA, Barocas DA, Chu CE, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026). J Urol. 2026;216(1):2-11. doi:10.1097/JU.0000000000005060. Full guideline: 2022; amended 2026; AUA Board approval February 2026.

65. Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024;211(4):509-517. doi:10.1097/JU.0000000000003892

66. Breyer BN, Kim SK, Kirkby E, Marianes A, Vanni AJ, Westney OL. "Updates to Incontinence After Prostate Treatment: AUA/GURS/SUFU Guideline (2024)." J Urol. 2024;212(4):531-538. doi:10.1097/JU.0000000000004088

67. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Distress Management. Version 2.2024. Guideline.

68. Ivan SJ, Lee M, Simhan J. "Contemporary management of radiation-associated posterior urethral stenosis: a narrative review." Transl Androl Urol. 2025;14(10):3377-3386. doi:10.21037/tau-2025-183

69. Ma YC, Lin L, Luo Z, Jin T. "Smoking is an independent risk factor for stricture recurrence after the urethroplasty: a systematic review and meta-analysis." Int Braz J Urol. 2023;49(1):8-23. doi:10.1590/S1677-5538.IBJU.2022.0244

70. Cahill E, Islam R, Chua K, et al. "Smoking is not associated with wound complications in augmented urethroplasty: a NSQIP analysis." Int Urol Nephrol. 2024;56(11):3479-3484. doi:10.1007/s11255-024-04085-7

71. Fazili T, Bhat TR, Masood S, Palmer JH, Mufti GR. "Fate of the leftover bladder after supravesical urinary diversion for benign disease." J Urol. 2006;176(2):620-621. doi:10.1016/j.juro.2006.03.056

72. Ikwuezunma G, Kedzior T, Abbasi A, et al. "Combined Urogynecology and Gynecologic Oncology Surgery Complications." Urogynecology (Phila). 2026. doi:10.1097/SPV.0000000000001864

73. U.S. Food and Drug Administration. Chantix (varenicline) tablets: prescribing information. Revised June 2025. FDA label.